Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
Novo Nordisk's CagriSema is turning heads with new phase 3 data showing it beats tirzepatide for weight loss in adults with type 2 diabetes — and delivers a 21% body weight reduction in people with obesity. The fixed-dose combo of cagrilintide and semaglutide is still investigational, but an FDA decision is expected by late 2026. The results span multiple trials and patient populations, cementing CagriSema as a serious next-gen contender in the obesity and diabetes space.
Novo Nordisk's investigational CagriSema — a once-weekly fixed-dose combo of the amylin analogue cagrilintide and GLP-1 receptor agonist semaglutide — is building an impressive phase 3 track record across multiple trials and patient populations. The drug works by simultaneously curbing hunger and boosting satiety through two complementary hormonal pathways.
In the REIMAGINE 5 trial, adults with type 2 diabetes (T2D) inadequately controlled on metformin or an SGLT2 inhibitor saw 12.4% weight loss with CagriSema 1mg/1mg vs. 9.1% with tirzepatide 5mg at 60 weeks — a statistically superior result. HbA1c reductions were comparable between the two drugs (–1.71% vs. –1.67%), confirming noninferiority. Meanwhile, in the REDEFINE 9 trial among adults with overweight or obesity, CagriSema 1mg/1mg drove a 21% reduction in body weight vs. just 2% with placebo at 68 weeks, along with improvements in blood pressure, waist-to-height ratio, and lipid profiles.
By the Numbers
Why it matters: With a New Drug Application already filed and an FDA decision expected by Q4 2026, CagriSema could soon reshape how clinicians approach obesity and T2D management — potentially offering a more potent option than existing GLP-1 therapies alone.
